Research progress of BCL-2 family apoptotic regulation and its mediated drug resistance after antitumor drug therapy_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

CHEN Cong ^1,2 , HAO Jianqi ^1,2 , PENG Haoning ^1,2 ,  LIU Lunxu ^1,2

1. Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China;
2. Chest Oncology Institute, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China;

Corresponding author：

LIU Lunxu, Email: lunxu_liu@aliyun.com

Keywords：

Apoptosis; BCL-2 family; antitumor drug resistance; specific inhibitors against apoptotic BCL-2 family members; review

DOI：

10.7507/1007-4848.202104023

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Apoptosis is an important means to regulate cell proliferation and maintain homeostasis. Recent researches have shown that the B-cell lymphoma-2 (BCL-2) family not only plays a dominant role in the regulation of normal cell apoptosis, but also plays a crucial role in the formation of tumor genesis, progression and subsequent drug resistance mediated by the escape mode of apoptosis. The phenomenon that BCL-2 family antagonized the apoptosis induced by antitumor drugs and then acquired drug resistance has been reported in the clinical treatment of hematologic lymphatic system tumors, breast cancer, lung cancer, gastric cancer and other diseases. Thus, specific inhibitors targeting anti-apoptotic members of the BCL-2 family have emerged with the development of research. In this paper, we systematically reviewed the regulation of apoptosis mediated by BCL-2 family and the drug resistance mediated by BCL-2 family. Meanwhile, we summarized the research advances of BCL-2 family specific inhibitors to provide new strategy for solving the problems on tumor therapeutic resistance and for finding new therapeutic targets in the future.

Citation： CHEN Cong, HAO Jianqi, PENG Haoning, LIU Lunxu. Research progress of BCL-2 family apoptotic regulation and its mediated drug resistance after antitumor drug therapy. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2023, 30(1): 140-148. doi: 10.7507/1007-4848.202104023 Copy

1.	Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer, 1972, 26(4): 239-257.
2.	Farbman AI. Electron microscope study of palate fusion in mouse embryos. Dev Biol, 1968, 18(2): 93-116.
3.	Klion FM, Schaffner F. The ultrastructure of acidophilic "Councilman-like" bodies in the liver. Am J Pathol, 1966, 48(5): 755-767.
4.	Su Z, Yang Z, Xu Y, et al. Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer, 2015, 14: 48.
5.	Mohammad RM, Muqbil I, Lowe L, et al. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol, 2015, 35 Suppl(0): S78-S103.
6.	Bakhshi A, Jensen JP, Goldman P, et al. Cloning the chromosomal breakpoint of t(14; 18) human lymphomas: Clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell, 1985, 41(3): 899-906.
7.	Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell, 1986, 47(1): 19-28.
8.	Maji S, Panda S, Samal SK, et al. Bcl-2 antiapoptotic family proteins and chemoresistance in cancer. Adv Cancer Res, 2018, 137: 37-75.
9.	Youle RJ, Strasser A. The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol, 2008, 9(1): 47-59.
10.	Elkholi R, Floros KV, Chipuk JE. The role of BH3-only proteins in tumor cell development, signaling, and treatment. Genes Cancer, 2011, 2(5): 523-537.
11.	Pawlowski J, Kraft AS. Bax-induced apoptotic cell death. Proc Natl Acad Sci U S A, 2000, 97(2): 529-531.
12.	Westphal D, Dewson G, Czabotar PE, et al. Molecular biology of Bax and Bak activation and action. Biochim Biophys Acta, 2011, 1813(4): 521-531.
13.	Leu JI, Dumont P, Hafey M, et al. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol, 2004, 6(5): 443-450.
14.	Llambi F, Wang YM, Victor B, et al. BOK is a non-canonical BCL-2 family effector of apoptosis regulated by ER-associated degradation. Cell, 2016, 165(2): 421-433.
15.	Yakovlev AG, Di Giovanni S, Wang G, et al. BOK and NOXA are essential mediators of p53-dependent apoptosis. J Biol Chem, 2004, 279(27): 28367-28374.
16.	Grespi F, Soratroi C, Krumschnabel G, et al. BH3-only protein Bmf mediates apoptosis upon inhibition of CAP-dependent protein synthesis. Cell Death Differ, 2010, 17(11): 1672-1683.
17.	Han J, Goldstein LA, Hou W, et al. Regulation of mitochondrial apoptotic events by p53-mediated disruption of complexes between antiapoptotic Bcl-2 members and Bim. J Biol Chem, 2010, 285(29): 22473-22483.
18.	Rousalova I, Krepela E. Granzyme B-induced apoptosis in cancer cells and its regulation (review). Int J Oncol, 2010, 37(6): 1361-1378.
19.	Kim H, Rafiuddin-Shah M, Tu HC, et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol, 2006, 8(12): 1348-1358.
20.	Shukla S, Saxena S, Singh BK, et al. BH3-only protein BIM: An emerging target in chemotherapy. Eur J Cell Biol, 2017, 96(8): 728-738.
21.	Esposti MD. The roles of Bid. Apoptosis, 2002, 7(5): 433-440.
22.	Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene, 2008, 27 Suppl 1(Suppl 1): S71-S83.
23.	Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell, 2001, 7(3): 683-694.
24.	Ploner C, Kofler R, Villunger A. Noxa: At the tip of the balance between life and death. Oncogene, 2008, 27 Suppl 1(Suppl 1): S84-S92.
25.	Chipuk JE, Bouchier-Hayes L, Kuwana T, et al. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science, 2005, 309(5741): 1732-1735.
26.	Jiang P, Du W, Wu M. P53 and Bad: Remote strangers become close friends. Cell Res, 2007, 17(4): 283-285.
27.	Howells CC, Baumann WT, Samuels DC, et al. The Bcl-2-associated death promoter (BAD) lowers the threshold at which the Bcl-2-interacting domain death agonist (BID) triggers mitochondria disintegration. J Theor Biol, 2011, 271(1): 114-123.
28.	Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science, 2000, 288(5468): 1053-1058.
29.	Shamas-Din A, Kale J, Leber B, et al. Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb Perspect Biol, 2013, 5(4): a008714.
30.	Greenberg EF, Lavik AR, Distelhorst CW. Bcl-2 regulation of the inositol 1, 4, 5-trisphosphate receptor and calcium signaling in normal and malignant lymphocytes: Potential new target for cancer treatment. Biochim Biophys Acta, 2014, 1843(10): 2205-2210.
31.	Thomas S, Quinn BA, Das SK, et al. Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets, 2013, 17(1): 61-75.
32.	Frenzel A, Grespi F, Chmelewskij W, et al. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis, 2009, 14(4): 584-596.
33.	Ozretic P, Alvir I, Sarcevic B, et al. Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients. Int J Biol Markers, 2018, 33(1): 109-115.
34.	Yang D, Chen MB, Wang LQ, et al. Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: A systematic review and meta-analysis. J Exp Clin Cancer Res, 2013, 32(1): 105.
35.	Villar E, Redondo M, Rodrigo I, et al. Bcl-2 expression and apoptosis in primary and metastatic breast carcinomas. Tumour Biol, 2001, 22(3): 137-145.
36.	Huang Q, Li S, Cheng P, et al. High expression of anti-apoptotic protein Bcl-2 is a good prognostic factor in colorectal cancer: Result of a meta-analysis. World J Gastroenterol, 2017, 23(27): 5018-5033.
37.	Itoi T, Yamana K, Bilim V, et al. Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients. Br J Cancer, 2004, 90(1): 200-205.
38.	Shibata Y, Hidaka S, Tagawa Y, et al. Bcl-2 protein expression correlates with better prognosis in patients with advanced non-small cell lung cancer. Anticancer Res, 2004, 24(3b): 1925-1928.
39.	Trisciuoglio D, Tupone MG, Desideri M, et al. BCL-X_L overexpression promotes tumor progression-associated properties. Cell Death Dis, 2017, 8(12): 3216.
40.	Kaufmann T, Schinzel A, Borner C. Bcl-w(edding) with mitochondria. Trends Cell Biol, 2004, 14(1): 8-12.
41.	Bae IH, Park MJ, Yoon SH, et al. Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1. Cancer Res, 2006, 66(10): 4991-4995.
42.	Wilson JW, Nostro MC, Balzi M, et al. Bcl-w expression in colorectal adenocarcinoma. Br J Cancer, 2000, 82(1): 178-185.
43.	Adams CM, Kim AS, Mitra R, et al. BCL-W has a fundamental role in B cell survival and lymphomagenesis. J Clin Invest, 2017, 127(2): 635-650.
44.	Adams CM, Mitra R, Gong JZ, et al. Non-hodgkin and hodgkin lymphomas select for overexpression of BCLW. Clin Cancer Res, 2017, 23(22): 7119-7129.
45.	Vogler M. BCL2A1: The underdog in the BCL2 family. Cell Death Differ, 2012, 19(1): 67-74.
46.	Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function. FEBS Lett, 2010, 584(14): 2981-2989.
47.	Hind CK, Carter MJ, Harris CL, et al. Role of the pro-survival molecule Bfl-1 in melanoma. Int J Biochem Cell Biol, 2015, 59: 94-102.
48.	Oakes SA, Scorrano L, Opferman JT, et al. Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum. Proc Natl Acad Sci U S A, 2005, 102(1): 105-110.
49.	Distelhorst CW, Bootman MD. Bcl-2 interaction with the inositol 1, 4, 5-trisphosphate receptor: Role in Ca(2+) signaling and disease. Cell Calcium, 2011, 50(3): 234-241.
50.	Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev, 2007, 87(1): 99-163.
51.	Stahnke K, Fulda S, Friesen C, et al. Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy. Blood, 2001, 98(10): 3066-3073.
52.	Igney FH, Krammer PH. Death and anti-death: Tumour resistance to apoptosis. Nat Rev Cancer, 2002, 2(4): 277-288.
53.	Zhou Y, Liu H, Xue R, et al. BH3 mimetic ABT-199 enhances the sensitivity of gemcitabine in pancreatic cancer in vitro and in vivo. Dig Dis Sci, 2018, 63(12): 3367-3375.
54.	Strasser A, Harris AW, Jacks T, et al. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell, 1994, 79(2): 329-339.
55.	Minn AJ, Rudin CM, Boise LH, et al. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood, 1995, 86(5): 1903-1910.
56.	Williams J, Lucas PC, Griffith KA, et al. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol, 2005, 96(2): 287-295.
57.	Han JY, Hong EK, Choi BG, et al. Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer. Med Oncol, 2003, 20(4): 355-362.
58.	Michaud WA, Nichols AC, Mroz EA, et al. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res, 2009, 15(5): 1645-1654.
59.	Erovic BM, Pelzmann M, Grasl MCh, et al. Mcl-1, vascular endothelial growth factor-R2, and 14-3-3sigma expression might predict primary response against radiotherapy and chemotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Clin Cancer Res, 2005, 11(24 Pt 1): 8632-8636.
60.	Jin J, Xiong Y, Cen B. Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer. Anticancer Drugs, 2017, 28(10): 1141-1149.
61.	Miquel C, Borrini F, Grandjouan S, et al. Role of bax mutations in apoptosis in colorectal cancers with microsatellite instability. Am J Clin Pathol, 2005, 123(4): 562-570.
62.	Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer, 1997, 76(7): 935-938.
63.	Pepper C, Thomas A, Hoy T, et al. Chlorambucil resistance in B-cell chronic lymphocytic leukaemia is mediated through failed Bax induction and selection of high Bcl-2-expressing subclones. Br J Haematol, 1999, 104(3): 581-588.
64.	Pepper C, Lin TT, Pratt G, et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood, 2008, 112(9): 3807-3817.
65.	Johnston JB, Daeninck P, Verburg L, et al. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma, 1997, 26(5-6): 435-449.
66.	Stoetzer OJ, Pogrebniak A, Scholz M, et al. Drug-induced apoptosis in chronic lymphocytic leukemia. Leukemia, 1999, 13(11): 1873-1880.
67.	Olie RA, Zangemeister-Wittke U. Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: Progress and therapeutic potential. Drug Resist Updat, 2001, 4(1): 9-15.
68.	O'Brien S, Moore JO, Boyd TE, et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phaseⅢ trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol, 2009, 27(31): 5208-5212.
69.	Raab R, Sparano JA, Ocean AJ, et al. A phaseⅠtrial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma. Am J Clin Oncol, 2010, 33(1): 61-65.
70.	Galatin PS, Advani RH, Fisher GA, et al. PhaseⅠtrial of oblimersen (Genasense^®) and gemcitabine in refractory and advanced malignancies. Invest New Drugs, 2011, 29(5): 971-977.
71.	Ott PA, Chang J, Madden K, et al. Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: A phaseⅠtrial. Cancer Chemother Pharmacol, 2013, 71(1): 183-191.
72.	Heere-Ress E, Thallinger C, Lucas T, et al. Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int J Cancer, 2002, 99(1): 29-34.
73.	Zangemeister-Wittke U, Leech SH, Olie RA, et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res, 2000, 6(6): 2547-2555.
74.	Sieghart W, Losert D, Strommer S, et al. Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy. J Hepatol, 2006, 44(1): 151-157.
75.	Chang BS, Minn AJ, Muchmore SW, et al. Identification of a novel regulatory domain in Bcl-X(L) and Bcl-2. EMBO J, 1997, 16(5): 968-977.
76.	Sattler M, Liang H, Nettesheim D, et al. Structure of Bcl-xL-Bak peptide complex: Recognition between regulators of apoptosis. Science, 1997, 275(5302): 983-986.
77.	Kolluri SK, Zhu X, Zhou X, et al. A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell, 2008, 14(4): 285-298.
78.	LaBelle JL, Katz SG, Bird GH, et al. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J Clin Invest, 2012, 122(6): 2018-2031.
79.	Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 2005, 435(7042): 677-681.
80.	van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell, 2006, 10(5): 389-399.
81.	Hann CL, Daniel VC, Sugar EA, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res, 2008, 68(7): 2321-2328.
82.	Wu H, Medeiros LJ, Young KH. Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances. Blood Rev, 2018, 32(1): 8-28.
83.	Tse C, Shoemaker AR, Adickes J, et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res, 2008, 68(9): 3421-3428.
84.	Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ, 2007, 14(5): 943-951.
85.	Gandhi L, Camidge DR, Ribeiro de Oliveira M, et al. PhaseⅠstudy of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol, 2011, 29(7): 909-916.
86.	Rudin CM, Hann CL, Garon EB, et al. PhaseⅡstudy of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res, 2012, 18(11): 3163-3169.
87.	Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol, 2012, 30(5): 488-496.
88.	Tolcher AW, LoRusso P, Arzt J, et al. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: Results of an open-label, phase 1 study. Cancer Chemother Pharmacol, 2015, 76(5): 1041-1049.
89.	Tolcher AW, LoRusso P, Arzt J, et al. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors. Cancer Chemother Pharmacol, 2015, 76(5): 1025-1032.
90.	Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med, 2013, 19(2): 202-208.
91.	Cang S, Iragavarapu C, Savooji J, et al. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol, 2015, 8: 129.
92.	Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med, 2019, 380(23): 2225-2236.
93.	Jain N, Keating M, Thompson P, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med, 2019, 380(22): 2095-2103.
94.	Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: An interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol, 2018, 19(1): 65-75.
95.	Davids MS, Roberts AW, Seymour JF, et al. PhaseⅠfirst-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol, 2017, 35(8): 826-833.
96.	Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phaseⅡ study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov, 2016, 6(10): 1106-1117.
97.	DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: A non-randomised, open-label, phase 1b study. Lancet Oncol, 2018, 19(2): 216-228.
98.	Cramer P, von Tresckow J, Bahlo J, et al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): Primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol, 2018, 19(9): 1215-1228.
99.	Wang G, Nikolovska-Coleska Z, Yang CY, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem, 2006, 49(21): 6139-6142.
100.	Zerp SF, Stoter R, Kuipers G, et al. AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis. Radiat Oncol, 2009, 4: 47.
101.	Stein MN, Goodin S, Gounder M, et al. A phaseⅠstudy of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors. Invest New Drugs, 2020, 38(3): 855-865.
102.	Swiecicki PL, Bellile E, Sacco AG, et al. A phaseⅡtrial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Invest New Drugs, 2016, 34(4): 481-489.
103.	Schelman WR, Mohammed TA, Traynor AM, et al. A phaseⅠstudy of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Invest New Drugs, 2014, 32(2): 295-302.
104.	Heist RS, Fain J, Chinnasami B, et al. PhaseⅠ/Ⅱ study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol, 2010, 5(10): 1637-1643.
105.	Espona-Fiedler M, Soto-Cerrato V, Hosseini A, et al. Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: Prodigiosin vs. obatoclax. Biochem Pharmacol, 2012, 83(4): 489-496.
106.	Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A, 2007, 104(49): 19512-19517.
107.	Goy A, Hernandez-Ilzaliturri FJ, Kahl B, et al. A phase Ⅰ/Ⅱ study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma. Leuk Lymphoma, 2014, 55(12): 2761-2768.
108.	Arellano ML, Borthakur G, Berger M, et al. A phase Ⅱ, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia. Clin Lymphoma Myeloma Leuk, 2014, 14(6): 534-539.

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer, 1972, 26(4): 239-257.
2. Farbman AI. Electron microscope study of palate fusion in mouse embryos. Dev Biol, 1968, 18(2): 93-116.
3. Klion FM, Schaffner F. The ultrastructure of acidophilic "Councilman-like" bodies in the liver. Am J Pathol, 1966, 48(5): 755-767.
4. Su Z, Yang Z, Xu Y, et al. Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer, 2015, 14: 48.
5. Mohammad RM, Muqbil I, Lowe L, et al. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol, 2015, 35 Suppl(0): S78-S103.
6. Bakhshi A, Jensen JP, Goldman P, et al. Cloning the chromosomal breakpoint of t(14; 18) human lymphomas: Clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell, 1985, 41(3): 899-906.
7. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell, 1986, 47(1): 19-28.
8. Maji S, Panda S, Samal SK, et al. Bcl-2 antiapoptotic family proteins and chemoresistance in cancer. Adv Cancer Res, 2018, 137: 37-75.
9. Youle RJ, Strasser A. The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol, 2008, 9(1): 47-59.
10. Elkholi R, Floros KV, Chipuk JE. The role of BH3-only proteins in tumor cell development, signaling, and treatment. Genes Cancer, 2011, 2(5): 523-537.
11. Pawlowski J, Kraft AS. Bax-induced apoptotic cell death. Proc Natl Acad Sci U S A, 2000, 97(2): 529-531.
12. Westphal D, Dewson G, Czabotar PE, et al. Molecular biology of Bax and Bak activation and action. Biochim Biophys Acta, 2011, 1813(4): 521-531.
13. Leu JI, Dumont P, Hafey M, et al. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol, 2004, 6(5): 443-450.
14. Llambi F, Wang YM, Victor B, et al. BOK is a non-canonical BCL-2 family effector of apoptosis regulated by ER-associated degradation. Cell, 2016, 165(2): 421-433.
15. Yakovlev AG, Di Giovanni S, Wang G, et al. BOK and NOXA are essential mediators of p53-dependent apoptosis. J Biol Chem, 2004, 279(27): 28367-28374.
16. Grespi F, Soratroi C, Krumschnabel G, et al. BH3-only protein Bmf mediates apoptosis upon inhibition of CAP-dependent protein synthesis. Cell Death Differ, 2010, 17(11): 1672-1683.
17. Han J, Goldstein LA, Hou W, et al. Regulation of mitochondrial apoptotic events by p53-mediated disruption of complexes between antiapoptotic Bcl-2 members and Bim. J Biol Chem, 2010, 285(29): 22473-22483.
18. Rousalova I, Krepela E. Granzyme B-induced apoptosis in cancer cells and its regulation (review). Int J Oncol, 2010, 37(6): 1361-1378.
19. Kim H, Rafiuddin-Shah M, Tu HC, et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol, 2006, 8(12): 1348-1358.
20. Shukla S, Saxena S, Singh BK, et al. BH3-only protein BIM: An emerging target in chemotherapy. Eur J Cell Biol, 2017, 96(8): 728-738.
21. Esposti MD. The roles of Bid. Apoptosis, 2002, 7(5): 433-440.
22. Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene, 2008, 27 Suppl 1(Suppl 1): S71-S83.
23. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell, 2001, 7(3): 683-694.
24. Ploner C, Kofler R, Villunger A. Noxa: At the tip of the balance between life and death. Oncogene, 2008, 27 Suppl 1(Suppl 1): S84-S92.
25. Chipuk JE, Bouchier-Hayes L, Kuwana T, et al. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science, 2005, 309(5741): 1732-1735.
26. Jiang P, Du W, Wu M. P53 and Bad: Remote strangers become close friends. Cell Res, 2007, 17(4): 283-285.
27. Howells CC, Baumann WT, Samuels DC, et al. The Bcl-2-associated death promoter (BAD) lowers the threshold at which the Bcl-2-interacting domain death agonist (BID) triggers mitochondria disintegration. J Theor Biol, 2011, 271(1): 114-123.
28. Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science, 2000, 288(5468): 1053-1058.
29. Shamas-Din A, Kale J, Leber B, et al. Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb Perspect Biol, 2013, 5(4): a008714.
30. Greenberg EF, Lavik AR, Distelhorst CW. Bcl-2 regulation of the inositol 1, 4, 5-trisphosphate receptor and calcium signaling in normal and malignant lymphocytes: Potential new target for cancer treatment. Biochim Biophys Acta, 2014, 1843(10): 2205-2210.
31. Thomas S, Quinn BA, Das SK, et al. Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets, 2013, 17(1): 61-75.
32. Frenzel A, Grespi F, Chmelewskij W, et al. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis, 2009, 14(4): 584-596.
33. Ozretic P, Alvir I, Sarcevic B, et al. Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients. Int J Biol Markers, 2018, 33(1): 109-115.
34. Yang D, Chen MB, Wang LQ, et al. Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: A systematic review and meta-analysis. J Exp Clin Cancer Res, 2013, 32(1): 105.
35. Villar E, Redondo M, Rodrigo I, et al. Bcl-2 expression and apoptosis in primary and metastatic breast carcinomas. Tumour Biol, 2001, 22(3): 137-145.
36. Huang Q, Li S, Cheng P, et al. High expression of anti-apoptotic protein Bcl-2 is a good prognostic factor in colorectal cancer: Result of a meta-analysis. World J Gastroenterol, 2017, 23(27): 5018-5033.
37. Itoi T, Yamana K, Bilim V, et al. Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients. Br J Cancer, 2004, 90(1): 200-205.
38. Shibata Y, Hidaka S, Tagawa Y, et al. Bcl-2 protein expression correlates with better prognosis in patients with advanced non-small cell lung cancer. Anticancer Res, 2004, 24(3b): 1925-1928.
39. Trisciuoglio D, Tupone MG, Desideri M, et al. BCL-X_L overexpression promotes tumor progression-associated properties. Cell Death Dis, 2017, 8(12): 3216.
40. Kaufmann T, Schinzel A, Borner C. Bcl-w(edding) with mitochondria. Trends Cell Biol, 2004, 14(1): 8-12.
41. Bae IH, Park MJ, Yoon SH, et al. Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1. Cancer Res, 2006, 66(10): 4991-4995.
42. Wilson JW, Nostro MC, Balzi M, et al. Bcl-w expression in colorectal adenocarcinoma. Br J Cancer, 2000, 82(1): 178-185.
43. Adams CM, Kim AS, Mitra R, et al. BCL-W has a fundamental role in B cell survival and lymphomagenesis. J Clin Invest, 2017, 127(2): 635-650.
44. Adams CM, Mitra R, Gong JZ, et al. Non-hodgkin and hodgkin lymphomas select for overexpression of BCLW. Clin Cancer Res, 2017, 23(22): 7119-7129.
45. Vogler M. BCL2A1: The underdog in the BCL2 family. Cell Death Differ, 2012, 19(1): 67-74.
46. Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function. FEBS Lett, 2010, 584(14): 2981-2989.
47. Hind CK, Carter MJ, Harris CL, et al. Role of the pro-survival molecule Bfl-1 in melanoma. Int J Biochem Cell Biol, 2015, 59: 94-102.
48. Oakes SA, Scorrano L, Opferman JT, et al. Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum. Proc Natl Acad Sci U S A, 2005, 102(1): 105-110.
49. Distelhorst CW, Bootman MD. Bcl-2 interaction with the inositol 1, 4, 5-trisphosphate receptor: Role in Ca(2+) signaling and disease. Cell Calcium, 2011, 50(3): 234-241.
50. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev, 2007, 87(1): 99-163.
51. Stahnke K, Fulda S, Friesen C, et al. Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy. Blood, 2001, 98(10): 3066-3073.
52. Igney FH, Krammer PH. Death and anti-death: Tumour resistance to apoptosis. Nat Rev Cancer, 2002, 2(4): 277-288.
53. Zhou Y, Liu H, Xue R, et al. BH3 mimetic ABT-199 enhances the sensitivity of gemcitabine in pancreatic cancer in vitro and in vivo. Dig Dis Sci, 2018, 63(12): 3367-3375.
54. Strasser A, Harris AW, Jacks T, et al. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell, 1994, 79(2): 329-339.
55. Minn AJ, Rudin CM, Boise LH, et al. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood, 1995, 86(5): 1903-1910.
56. Williams J, Lucas PC, Griffith KA, et al. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol, 2005, 96(2): 287-295.
57. Han JY, Hong EK, Choi BG, et al. Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer. Med Oncol, 2003, 20(4): 355-362.
58. Michaud WA, Nichols AC, Mroz EA, et al. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res, 2009, 15(5): 1645-1654.
59. Erovic BM, Pelzmann M, Grasl MCh, et al. Mcl-1, vascular endothelial growth factor-R2, and 14-3-3sigma expression might predict primary response against radiotherapy and chemotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Clin Cancer Res, 2005, 11(24 Pt 1): 8632-8636.
60. Jin J, Xiong Y, Cen B. Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer. Anticancer Drugs, 2017, 28(10): 1141-1149.
61. Miquel C, Borrini F, Grandjouan S, et al. Role of bax mutations in apoptosis in colorectal cancers with microsatellite instability. Am J Clin Pathol, 2005, 123(4): 562-570.
62. Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer, 1997, 76(7): 935-938.
63. Pepper C, Thomas A, Hoy T, et al. Chlorambucil resistance in B-cell chronic lymphocytic leukaemia is mediated through failed Bax induction and selection of high Bcl-2-expressing subclones. Br J Haematol, 1999, 104(3): 581-588.
64. Pepper C, Lin TT, Pratt G, et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood, 2008, 112(9): 3807-3817.
65. Johnston JB, Daeninck P, Verburg L, et al. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma, 1997, 26(5-6): 435-449.
66. Stoetzer OJ, Pogrebniak A, Scholz M, et al. Drug-induced apoptosis in chronic lymphocytic leukemia. Leukemia, 1999, 13(11): 1873-1880.
67. Olie RA, Zangemeister-Wittke U. Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: Progress and therapeutic potential. Drug Resist Updat, 2001, 4(1): 9-15.
68. O'Brien S, Moore JO, Boyd TE, et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phaseⅢ trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol, 2009, 27(31): 5208-5212.
69. Raab R, Sparano JA, Ocean AJ, et al. A phaseⅠtrial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma. Am J Clin Oncol, 2010, 33(1): 61-65.
70. Galatin PS, Advani RH, Fisher GA, et al. PhaseⅠtrial of oblimersen (Genasense^®) and gemcitabine in refractory and advanced malignancies. Invest New Drugs, 2011, 29(5): 971-977.
71. Ott PA, Chang J, Madden K, et al. Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: A phaseⅠtrial. Cancer Chemother Pharmacol, 2013, 71(1): 183-191.
72. Heere-Ress E, Thallinger C, Lucas T, et al. Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int J Cancer, 2002, 99(1): 29-34.
73. Zangemeister-Wittke U, Leech SH, Olie RA, et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res, 2000, 6(6): 2547-2555.
74. Sieghart W, Losert D, Strommer S, et al. Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy. J Hepatol, 2006, 44(1): 151-157.
75. Chang BS, Minn AJ, Muchmore SW, et al. Identification of a novel regulatory domain in Bcl-X(L) and Bcl-2. EMBO J, 1997, 16(5): 968-977.
76. Sattler M, Liang H, Nettesheim D, et al. Structure of Bcl-xL-Bak peptide complex: Recognition between regulators of apoptosis. Science, 1997, 275(5302): 983-986.
77. Kolluri SK, Zhu X, Zhou X, et al. A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell, 2008, 14(4): 285-298.
78. LaBelle JL, Katz SG, Bird GH, et al. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J Clin Invest, 2012, 122(6): 2018-2031.
79. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 2005, 435(7042): 677-681.
80. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell, 2006, 10(5): 389-399.
81. Hann CL, Daniel VC, Sugar EA, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res, 2008, 68(7): 2321-2328.
82. Wu H, Medeiros LJ, Young KH. Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances. Blood Rev, 2018, 32(1): 8-28.
83. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res, 2008, 68(9): 3421-3428.
84. Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ, 2007, 14(5): 943-951.
85. Gandhi L, Camidge DR, Ribeiro de Oliveira M, et al. PhaseⅠstudy of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol, 2011, 29(7): 909-916.
86. Rudin CM, Hann CL, Garon EB, et al. PhaseⅡstudy of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res, 2012, 18(11): 3163-3169.
87. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol, 2012, 30(5): 488-496.
88. Tolcher AW, LoRusso P, Arzt J, et al. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: Results of an open-label, phase 1 study. Cancer Chemother Pharmacol, 2015, 76(5): 1041-1049.
89. Tolcher AW, LoRusso P, Arzt J, et al. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors. Cancer Chemother Pharmacol, 2015, 76(5): 1025-1032.
90. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med, 2013, 19(2): 202-208.
91. Cang S, Iragavarapu C, Savooji J, et al. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol, 2015, 8: 129.
92. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med, 2019, 380(23): 2225-2236.
93. Jain N, Keating M, Thompson P, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med, 2019, 380(22): 2095-2103.
94. Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: An interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol, 2018, 19(1): 65-75.
95. Davids MS, Roberts AW, Seymour JF, et al. PhaseⅠfirst-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol, 2017, 35(8): 826-833.
96. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phaseⅡ study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov, 2016, 6(10): 1106-1117.
97. DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: A non-randomised, open-label, phase 1b study. Lancet Oncol, 2018, 19(2): 216-228.
98. Cramer P, von Tresckow J, Bahlo J, et al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): Primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol, 2018, 19(9): 1215-1228.
99. Wang G, Nikolovska-Coleska Z, Yang CY, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem, 2006, 49(21): 6139-6142.
100. Zerp SF, Stoter R, Kuipers G, et al. AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis. Radiat Oncol, 2009, 4: 47.
101. Stein MN, Goodin S, Gounder M, et al. A phaseⅠstudy of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors. Invest New Drugs, 2020, 38(3): 855-865.
102. Swiecicki PL, Bellile E, Sacco AG, et al. A phaseⅡtrial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Invest New Drugs, 2016, 34(4): 481-489.
103. Schelman WR, Mohammed TA, Traynor AM, et al. A phaseⅠstudy of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Invest New Drugs, 2014, 32(2): 295-302.
104. Heist RS, Fain J, Chinnasami B, et al. PhaseⅠ/Ⅱ study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol, 2010, 5(10): 1637-1643.
105. Espona-Fiedler M, Soto-Cerrato V, Hosseini A, et al. Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: Prodigiosin vs. obatoclax. Biochem Pharmacol, 2012, 83(4): 489-496.
106. Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A, 2007, 104(49): 19512-19517.
107. Goy A, Hernandez-Ilzaliturri FJ, Kahl B, et al. A phase Ⅰ/Ⅱ study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma. Leuk Lymphoma, 2014, 55(12): 2761-2768.
108. Arellano ML, Borthakur G, Berger M, et al. A phase Ⅱ, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia. Clin Lymphoma Myeloma Leuk, 2014, 14(6): 534-539.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Research progress of BCL-2 family apoptotic regulation and its mediated drug resistance after antitumor drug therapy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content